Information  X 
Enter a valid email address

ValiRx PLC (VAL)

  Print      Mail a friend

Thursday 09 April, 2020

ValiRx PLC

Change of Arrangements for General Meeting

RNS Number : 4182J
ValiRx PLC
09 April 2020




9 April 2020

ValiRx Plc

("ValiRx" or the "Company")



London, UK, 9 April 2020: ValiRx Plc (AIM: VAL), a clinical stage biotechnology company, announces that the COVID-19 lockdown makes attendance impossible by shareholders at the General Meeting requisitioned to be held at 11am on 14 April 2020. The directors who are not named in the requisition notice, being Kevin Alexander and Gerry Desler (together the "Independent Directors"), have been unable to find a suitable means for the shareholders participating and voting in person or remotely during the lockdown. However, the Independent Directors recognise that shareholders have already had the right to vote by proxy. Accordingly, the Independent Directors have decided to allow the proceedings to be determined on a poll vote based upon the proxies received for the General Meeting. There will be no vote by show of hands. Instead two shareholders (at least one of whom will be a director) will hold the meeting at the appointed time to constitute a quorum. The Independent Directors note that attendance at its shareholders' meetings has historically been low and that resolutions have always been voted upon in a way that is consistent with proxies that have been submitted. The Independent Directors regret that shareholders will be unable to participate and vote at the meeting but there is no alternative in the current circumstances.


The business to be conducted at the General Meeting remains as set out in the Notice of General Meeting and no other changes to the procedures for voting at and attending the General Meeting are proposed.  There will be no effect on voting instructions already given by way of proxy card or through or other intermediaries, which will remain valid. There will be no presentation or information provided at the General Meeting. The results of the General Meeting will be announced in the usual way.



For more information, please contact:


ValiRx plc

Tel: +44 (0) 20 3008 4416

Kevin Alexander, Non-Executive Director and Secretary

Tel: +44 (0) 20 3008 4416

Tarquin Edwards, Head of Communications

Tel: +44 (0) 7879 458 364

[email protected]

Cairn Financial Advisers LLP (Nominated Adviser)

Liam Murray / Jo Turner / Ludovico Lazzaretti

Tel: +44 (0) 20 7213 0880



Notes for Editors

About ValiRx

ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.


The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.


ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights.  They originate or derive from World class institutions, such as Cancer Research UK and Imperial College. 


Until recently, cancer treatments relied on non-specific agents, such as chemotherapy.  With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.


The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t